KR20190015275A - 메닌 억제제로서의 피페리딘 - Google Patents

메닌 억제제로서의 피페리딘 Download PDF

Info

Publication number
KR20190015275A
KR20190015275A KR1020187034933A KR20187034933A KR20190015275A KR 20190015275 A KR20190015275 A KR 20190015275A KR 1020187034933 A KR1020187034933 A KR 1020187034933A KR 20187034933 A KR20187034933 A KR 20187034933A KR 20190015275 A KR20190015275 A KR 20190015275A
Authority
KR
South Korea
Prior art keywords
cancer
cell
carcinoma
tumor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187034933A
Other languages
English (en)
Korean (ko)
Inventor
샤오멍 왕
안젤로 아길라
케 장
시린 수
티안펭 수
덴질 버나드
리유에 후앙
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시간 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시간
Publication of KR20190015275A publication Critical patent/KR20190015275A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187034933A 2016-05-02 2017-05-02 메닌 억제제로서의 피페리딘 Ceased KR20190015275A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330350P 2016-05-02 2016-05-02
US62/330,350 2016-05-02
PCT/US2017/030577 WO2017192543A1 (en) 2016-05-02 2017-05-02 Piperidines as menin inhibitors

Publications (1)

Publication Number Publication Date
KR20190015275A true KR20190015275A (ko) 2019-02-13

Family

ID=58699299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034933A Ceased KR20190015275A (ko) 2016-05-02 2017-05-02 메닌 억제제로서의 피페리딘

Country Status (13)

Country Link
US (2) US10899738B2 (https=)
EP (1) EP3452461B1 (https=)
JP (1) JP6991585B2 (https=)
KR (1) KR20190015275A (https=)
CN (1) CN109415337B (https=)
AU (1) AU2017259436B2 (https=)
BR (1) BR112018072570A2 (https=)
CA (1) CA3022868A1 (https=)
ES (1) ES2899936T3 (https=)
IL (2) IL262697B (https=)
MX (1) MX384087B (https=)
SG (1) SG11201809714TA (https=)
WO (1) WO2017192543A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
KR20200101389A (ko) 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP2021519785A (ja) * 2018-03-30 2021-08-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン化合物
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
EP3856173A4 (en) * 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS
BR112021006273A2 (pt) * 2018-10-03 2021-07-06 Agios Pharmaceuticals Inc inibidores de menin de pequenas moléculas
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
EP4334320A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AU2022271791A1 (en) * 2021-05-12 2024-01-04 Board Of Regents, The University Of Texas System Combinations for treatment of cancer
WO2022253167A1 (en) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
CA3220099A1 (en) 2021-06-17 2022-12-22 Wei Cai (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023225005A1 (en) * 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN120987784B (zh) * 2025-10-23 2026-03-20 辽宁鸿港化工有限公司 一种对甲氧基苄胺及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1998054167A1 (en) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Indole compounds
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US8242078B2 (en) 2006-10-19 2012-08-14 The University Of Chicago Therapeutics to inhibit MLL-menin interaction for treating leukemia
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012154194A1 (en) 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
KR20150130389A (ko) 2013-03-13 2015-11-23 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
US10899758B2 (en) 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
EP3856173A4 (en) 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS

Also Published As

Publication number Publication date
CA3022868A1 (en) 2017-11-09
IL281182A (en) 2021-04-29
WO2017192543A1 (en) 2017-11-09
JP2019514950A (ja) 2019-06-06
IL262697A (en) 2018-12-31
BR112018072570A2 (pt) 2019-02-19
US10899738B2 (en) 2021-01-26
EP3452461A1 (en) 2019-03-13
MX384087B (es) 2025-03-14
US20190152947A1 (en) 2019-05-23
AU2017259436B2 (en) 2021-08-26
ES2899936T3 (es) 2022-03-15
SG11201809714TA (en) 2018-11-29
US20210198237A1 (en) 2021-07-01
MX2018013433A (es) 2019-07-18
AU2017259436A1 (en) 2018-12-20
IL262697B (en) 2021-04-29
EP3452461B1 (en) 2021-09-08
CN109415337A (zh) 2019-03-01
JP6991585B2 (ja) 2022-01-12
CN109415337B (zh) 2022-01-18

Similar Documents

Publication Publication Date Title
EP3452461B1 (en) Piperidines as menin inhibitors
EP3440066B1 (en) Mdm2 protein degraders
JP7141399B2 (ja) ポリ－ａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤
JP2022527298A (ja) Ｓｔａｔ３の低分子分解誘導剤
EP3426243B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
CN117580592A (zh) 用于靶向布鲁顿酪氨酸激酶降解的化合物
JP2020515571A (ja) 共有結合性メニン阻害剤としてのピペリジン
AU2019243587A1 (en) Piperidine compounds as covalent menin inhibitors
TW202315870A (zh) 布魯頓氏酪胺酸激酶之抑制劑
AU2016279965A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
JP2023515095A (ja) 置換アリール系化合物
TW202204333A (zh) Menin抑制劑及治療癌症之使用方法
CA3112340A1 (en) Small molecule menin inhibitors
TW202126636A (zh) 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
HK40006016B (en) Piperidines as menin inhibitors
HK40006016A (en) Piperidines as menin inhibitors
CA3020275C (en) Mdm2 protein degraders
WO2025136811A1 (en) Chemical compounds and uses thereof
TW202502748A (zh) 用於調節stat3之化合物及方法
JP2024542036A (ja) Ｇｐｒ３９タンパク質のアンタゴニスト

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211030

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220509

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211030

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I